Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sumanirole · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| sumanirole | DRUG | - |
| ropinirole | DRUG | - |
Inclusion Criteria: Idiopathic Parkinson's disease \< 7 years duration Modified Hoehn and Yahr Scale Stages I through III Age greater than or equal to 30 years old Patients or their partners must use adequate contraceptive methods Patients who are willing and able to comply with scheduled visit...
Sumanirole is an investigational small molecule being developed for the treatment of the signs and symptoms of early Parkinson's disease. It is being studied in patients aged 30 years and older. The drug is not approved and remains in clinical development.
Sumanirole is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical trials for Parkinson's disease.
Sumanirole is in Phase 3 clinical development for early Parkinson's disease. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug is not yet available commercially.
Sumanirole has been studied in two completed Phase 3 trials: NCT00036218 with 600 participants and NCT00058838 with 854 participants, both evaluating the drug for early Parkinson's disease. These trials were conducted in multiple countries including the United States, Argentina, Mexico, and several European nations.
Sumanirole is a distinct investigational compound developed by Pfizer. It is not known to be the same as any other marketed drug. Its mechanism of action has not been disclosed in available clinical trial information.